Leadership

Executive Team

Peyton Anderson, MBA
Chief Executive Officer

Peyton is a successful entrepreneur who co-founded SciQuest, Inc. in 1995 as its founding CEO. SciQuest raised over $175 million in capital, including a successful Initial Public Offering in 1999. His responsibilities included raising capital, recruiting the management team, doing strategic partner deals, and orchestrating 8 acquisitions. SciQuest has continued to thrive and currently has greater than 150 employees.

Peyton joined Affinergy in September 2003 as founding CEO. Since that time, Affinergy has secured $5m in investor funding, been awarded numerous peer-review grants, added 23 employees, recruited a strong team of advisors / Board members, and committed to developing multiple products in the orthopedic and soft tissue repair markets.

Peyton will continue to expand Affinergy's leadership team by recruiting professionals in quality, manufacturing, clinical, sales, and marketing.

Peyton currently serves on the Board of Directors of the North Carolina Biotechnology Center and the NC Biosciences Organization. Previously, he served on the executive committee of the Board of Directors for the Council for Entrepreneurial Development.

Peyton is a frequent speaker at entrepreneurial conferences and MBA classes. Peyton graduated Phi Beta Kappa from the U. of Richmond in 1989 and earned his MBA from UNC's Kenan Flagler Business School in 1995.

Jonathan Gindes, MBA, RAC
Chief Financial Officer and Senior Vice-President of Business Development

Jonathan and Affinergy's scientific co-founders (M. Grinstaff, D. Kenan) began working together in 2002 to form Affinergy while Jonathan pursued his M.B.A. at Duke's Fuqua School of Business. Jonathan developed Affinergy's initial business strategy, negotiated the technology license from Duke University, and recruited a senior management team along with other scientific staff and business advisors.

Presently, in addition to managing Affinergy’s daily financial affairs, Jonathan focuses his time procuring sufficient capital to enable the rapid growth of Affinergy, whether through grants and other growth capital sources. Jonathan plays an active role on the operations side of Affinergy, as well, and supervises the sourcing of all of Affinergy’s equipment and supplies. He also is responsible for securing relationships and supply agreements with component suppliers for Affinergy’s future products.

Prior to attending Fuqua, Jonathan spent several years working alongside senior management in the corporate strategy group at Deutsche Bank. His work focused on merger integration, growth and consolidation strategies, and business plan development for potential spinouts.

Jonathan received his Bachelor of Arts degree in Economics from Rutgers University. He serves on the board of the Council for Entrepreneurial Development as well as Fuqua’s Entrepreneurship and Venture Capital Club and is a frequent lecturer to Global Executive and Full-Time MBA programs at the Fuqua School of Business. He also became certified in regulatory affairs (RAC) in 2009 and was recently a recipient of the Triangle Business Journal’s CFO of the year award.

Bruce Lamb, Ph.D.
Senior Vice-President of Research & Development

Bruce brings to Affinergy over 23 years of leadership experience in developing medical devices in the biosurgical area. He was most recently SVP of R&D and Regulatory Affairs at Lifecell which was acquired for $1.8 billion in 2008. Previously, Bruce was VP of Worldwide R&D for Biosurgicals at J&J's Ethicon division. Bruce also previously held leadership roles in product development at Convatec as well as Pfizer's Hospital Products Group.

Bruce earned his Ph.D. in Polymer Chemistry at SUNY College of ESF, Syracuse. He earned his M.S. in Chemistry at the University of Wisconsin, Milwaukee and his B.S. in Chemistry at Bradley University.

Daniel Kenan, M.D., Ph.D.
Scientific Co-Founder

Dan is an Assistant Professor of Pathology at Duke University Medical Center. Dan received his Ph.D. in Microbiology and Immunology at Duke. He later received his M.D. at Duke where he continued residency training in Pathology.

In 1997, Dan became the Director of the Combinatorial Sciences Center at Duke. Dan has published more than 30 manuscripts and is the principal investigator on 4 NIH grants.

Mark Grinstaff, Ph.D.
Scientific Co-Founder

Mark is an Associate Professor of Chemistry and Biomedical Engineering at Boston University. This professorship is funded by a $14MM Whitaker Foundation Leadership Award. Mark received his Ph.D. from U. of Illinois and was an NIH Postdoctoral Fellow at the California Institute of Technology.

Mark has published over 60 manuscripts. His awards include the ACS Nobel Laureate Signature Award, NSF Career Award, Pew Scholar in the Biomedical Sciences, Camille Dreyfus Teacher-Scholar, and an Alfred P. Sloan Research Fellowship.

Key Advisors